FGF21型
内分泌学
内科学
胰岛素抵抗
2型糖尿病
胰岛素
脂肪组织
非酒精性脂肪肝
白色脂肪组织
骨骼肌
葡萄糖钳夹技术
生物
脂肪肝
神经酰胺
糖尿病
医学
胰腺激素
成纤维细胞生长因子
生物化学
受体
细胞凋亡
疾病
作者
João Paulo Camporez,François R. Jornayvaz,Max C. Petersen,Dominik Hans Pesta,Blas A. Guigni,Julie Serr,Dongyan Zhang,Mario Kahn,Varman T. Samuel,Michael J. Jurczak,Gerald I. Shulman
出处
期刊:Endocrinology
[Oxford University Press]
日期:2013-06-13
卷期号:154 (9): 3099-3109
被引量:231
摘要
Fibroblast growth factor 21 (FGF21) is a potent regulator of glucose and lipid metabolism and is currently being pursued as a therapeutic agent for insulin resistance and type 2 diabetes. However, the cellular mechanisms by which FGF21 modifies insulin action in vivo are unclear. To address this question, we assessed insulin action in regular chow- and high-fat diet (HFD)-fed wild-type mice chronically infused with FGF21 or vehicle. Here, we show that FGF21 administration results in improvements in both hepatic and peripheral insulin sensitivity in both regular chow- and HFD-fed mice. This improvement in insulin responsiveness in FGF21-treated HFD-fed mice was associated with decreased hepatocellular and myocellular diacylglycerol content and reduced protein kinase Cε activation in liver and protein kinase Cθ in skeletal muscle. In contrast, there were no effects of FGF21 on liver or muscle ceramide content. These effects may be attributed, in part, to increased energy expenditure in the liver and white adipose tissue. Taken together, these data provide a mechanism by which FGF21 protects mice from lipid-induced liver and muscle insulin resistance and support its development as a novel therapy for the treatment of nonalcoholic fatty liver disease, insulin resistance, and type 2 diabetes.
科研通智能强力驱动
Strongly Powered by AbleSci AI